Mold Illness and CIRS Claims Denied by Insurance: How to Appeal

Chronic Inflammatory Response Syndrome (CIRS) — also called biotoxin illness or mold illness — is a condition recognized by a growing body of medical literature and an active community of treating clinicians, yet it faces significant skepticism from insurance companies. If your insurer denied CIRS-related testing, specialist care, or treatment as "experimental," "not medically necessary," or not a recognized diagnosis, this guide explains the landscape and how to approach your appeal.

Why CIRS Claims Are Frequently Denied

Diagnostic controversy: CIRS is not listed in the ICD-10 as a standalone diagnosis, which creates billing and coverage complications. Insurers may challenge claims coded under related conditions (toxic effects, unspecified connective tissue disorders, or multisystem inflammatory conditions) by arguing the underlying condition lacks sufficient diagnostic recognition.

VCS (Visual Contrast Sensitivity) Testing: VCS testing is used by CIRS practitioners to assess neurological involvement consistent with biotoxin exposure. Insurers routinely deny VCS testing as experimental or not medically necessary, citing lack of mainstream clinical guideline endorsement.

HLA-DR Testing and Specialty Labs: Genetic susceptibility testing (HLA-DR haplotype analysis) used in CIRS evaluation is often denied as experimental or excluded from covered laboratory benefits. Specialty tests run through specific reference laboratories may also be denied as out-of-network.

Specialist Fees: When patients travel to see CIRS-specialized physicians, out-of-network denials compound the coverage problem. Balance billing and out-of-network cost-sharing can be substantial.

Treatment Protocols: Cholestyramine, VIP (vasoactive intestinal polypeptide), and other treatments used in CIRS protocols face denial as experimental, off-label, or not meeting standard-of-care criteria.

The Experimental Designation Challenge

The most common insurer argument against CIRS treatment coverage is that the diagnosis and treatment protocols are experimental or investigational. This argument has several weaknesses that can be exploited in an appeal:

Peer-reviewed literature exists: Research by Dr. Ritchie Shoemaker and others has been published in peer-reviewed journals. While mainstream specialty societies have not endorsed CIRS protocols as standard of care, a body of published evidence does exist. Your physician can cite specific publications in the appeal.

Comparable diagnostic ambiguity: Insurers cover many conditions for which diagnostic criteria remain evolving or contested. A well-crafted appeal can argue that the insurer applies a different standard of evidence to CIRS than to other conditions of similar diagnostic complexity. Request the insurer's clinical evidence review process in writing to document this potential inconsistency.

Symptom-based coding strategy: When appealing, your physician may use ICD-10 codes that describe documented, measurable findings rather than the CIRS label itself — MCS (multiple chemical sensitivity, T65.9x), inflammatory markers, neurological symptoms, and pulmonary findings all have ICD-10 representations. Coverage arguments based on documented, measurable abnormalities are often stronger than arguments based solely on the CIRS diagnosis.

Strategies for Building Your Appeal

Document objective findings: Lab abnormalities (elevated MMP-9, low MSH, VEGF dysregulation, complement abnormalities), pulmonary function test results, neurological findings on exam, cognitive testing results — anything measurable and documented supports medical necessity arguments for evaluation and treatment.

Use a multisystem narrative: CIRS manifests across multiple organ systems. Frame the medical necessity argument around the treating physician's need to evaluate and manage documented, measurable abnormalities in each affected system rather than around the CIRS label alone.

Argue against the experimental designation: Request the insurer's specific evidence review and criteria used to classify the treatment or testing as experimental. Challenge whether the insurer's process meets the requirements of your plan documents and state law. Many state insurance regulations require that experimental determinations be made according to specific, objective criteria.

Get specialist documentation: A physician who specializes in CIRS treatment and can articulate the clinical evidence base — and directly respond to the insurer's specific denial criteria — is essential for a serious appeal.

Consider an appeal for documented comorbidities: CIRS patients often have comorbid conditions (POTS, sleep disorders, cognitive impairment, musculoskeletal symptoms) that are more broadly recognized. Appeals for covered management of these comorbidities, even if the underlying CIRS diagnosis is contested, may succeed.

External Independent Review: Complete Guide" class="auto-link">External Review

Independent external review is available for all ACA-compliant plans. An external reviewer who has familiarity with complex multi-system inflammatory conditions may be more receptive to the clinical evidence than the insurer's internal reviewers. Request that the external reviewer have relevant specialty expertise, and provide your physician's detailed explanation of the evidence base with the external review request.

Fight Back With ClaimBack

The medical system is still catching up on CIRS, but that doesn't mean you have to accept a denial without a fight. ClaimBack helps patients with complex, contested conditions build the most credible possible appeal.

Start your mold illness/CIRS insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Common Reasons Insurance Claims Are Denied